These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 34887143)
1. Associations of Race and Ethnicity With Presentation and Outcomes of Hypertrophic Cardiomyopathy: JACC Focus Seminar 6/9. Ntusi NAB; Sliwa K J Am Coll Cardiol; 2021 Dec; 78(25):2573-2579. PubMed ID: 34887143 [TBL] [Abstract][Full Text] [Related]
2. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. Eberly LA; Day SM; Ashley EA; Jacoby DL; Jefferies JL; Colan SD; Rossano JW; Semsarian C; Pereira AC; Olivotto I; Ingles J; Seidman CE; Channaoui N; Cirino AL; Han L; Ho CY; Lakdawala NK JAMA Cardiol; 2020 Jan; 5(1):83-91. PubMed ID: 31799990 [TBL] [Abstract][Full Text] [Related]
3. Impact of Racial and Ethnic Disparities on Patients With Dilated Cardiomyopathy: JACC Focus Seminar 7/9. Ntusi NAB; Sliwa K J Am Coll Cardiol; 2021 Dec; 78(25):2580-2588. PubMed ID: 34887144 [TBL] [Abstract][Full Text] [Related]
4. Inequities in Treatments and Outcomes Among Patients Hospitalized With Hypertrophic Cardiomyopathy in the United States. Johnson DY; Waken RJ; Fox DK; Hammond G; Joynt Maddox KE; Cresci S J Am Heart Assoc; 2023 Jun; 12(11):e029930. PubMed ID: 37232238 [TBL] [Abstract][Full Text] [Related]
5. Clinical Profile and Health Disparities in a Multiethnic Cohort of Patients With Hypertrophic Cardiomyopathy. Butters A; Semsarian CR; Bagnall RD; Yeates L; Stafford F; Burns C; Semsarian C; Ingles J Circ Heart Fail; 2021 Mar; 14(3):e007537. PubMed ID: 33724884 [TBL] [Abstract][Full Text] [Related]
6. Disease Expression and Outcomes in Black and White Adults With Hypertrophic Cardiomyopathy. Arabadjian ME; Yu G; Sherrid MV; Dickson VV J Am Heart Assoc; 2021 Sep; 10(17):e019978. PubMed ID: 34431363 [TBL] [Abstract][Full Text] [Related]
7. Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Maron BJ; Rowin EJ; Casey SA; Lesser JR; Garberich RF; McGriff DM; Maron MS Circulation; 2016 Jan; 133(1):62-73. PubMed ID: 26518766 [TBL] [Abstract][Full Text] [Related]
8. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970 [TBL] [Abstract][Full Text] [Related]
9. Association Between Race and Clinical Profile of Patients Referred for Hypertrophic Cardiomyopathy. Wells S; Rowin EJ; Bhatt V; Maron MS; Maron BJ Circulation; 2018 May; 137(18):1973-1975. PubMed ID: 29712699 [No Abstract] [Full Text] [Related]
11. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience. Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403 [TBL] [Abstract][Full Text] [Related]
12. Management of hypertrophic cardiomyopathy. Enriquez AD; Goldman ME Ann Glob Health; 2014; 80(1):35-45. PubMed ID: 24751563 [TBL] [Abstract][Full Text] [Related]
13. Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy. Patlolla SH; Schaff HV; Nishimura RA; Eleid MF; Geske JB; Ommen SR J Am Heart Assoc; 2023 Jan; 12(1):e026661. PubMed ID: 36565202 [TBL] [Abstract][Full Text] [Related]
14. Current perspectives in hypertrophic cardiomyopathy with the focus on patients in the Finnish population: a review. Kuusisto J; Sipola P; Jääskeläinen P; Naukkarinen A Ann Med; 2016 Nov; 48(7):496-508. PubMed ID: 27460395 [TBL] [Abstract][Full Text] [Related]
15. Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. Maron BJ; Ommen SR; Semsarian C; Spirito P; Olivotto I; Maron MS J Am Coll Cardiol; 2014 Jul; 64(1):83-99. PubMed ID: 24998133 [TBL] [Abstract][Full Text] [Related]
16. Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. Rowin EJ; Maron BJ; Haas TS; Garberich RF; Wang W; Link MS; Maron MS J Am Coll Cardiol; 2017 Feb; 69(7):761-773. PubMed ID: 28209216 [TBL] [Abstract][Full Text] [Related]
17. Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. Maron BJ; Rowin EJ; Casey SA; Link MS; Lesser JR; Chan RH; Garberich RF; Udelson JE; Maron MS J Am Coll Cardiol; 2015 May; 65(18):1915-28. PubMed ID: 25953744 [TBL] [Abstract][Full Text] [Related]
19. Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy. Rowin EJ; Maron MS; Wells S; Patel PP; Koethe BC; Maron BJ J Am Heart Assoc; 2019 Nov; 8(21):e012041. PubMed ID: 31663408 [TBL] [Abstract][Full Text] [Related]